These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11929387)

  • 1. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin.
    Gordon FH; Hamilton MI; Donoghue S; Greenlees C; Palmer T; Rowley-Jones D; Dhillon AP; Amlot PL; Pounder RE
    Aliment Pharmacol Ther; 2002 Apr; 16(4):699-705. PubMed ID: 11929387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.
    Gordon FH; Lai CW; Hamilton MI; Allison MC; Srivastava ED; Fouweather MG; Donoghue S; Greenlees C; Subhani J; Amlot PL; Pounder RE
    Gastroenterology; 2001 Aug; 121(2):268-74. PubMed ID: 11487536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab for active Crohn's disease.
    Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
    N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.
    Sandborn WJ; Cyrille M; Hansen MB; Feagan BG; Loftus EV; Rogler G; Vermeire S; Cruz ML; Yang J; Boedigheimer MJ; Abuqayyas L; Evangelista CM; Sullivan BA; Reinisch W
    Gastroenterology; 2019 Mar; 156(4):946-957.e18. PubMed ID: 30472236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab therapy for moderate to severe Crohn disease in adolescents.
    Hyams JS; Wilson DC; Thomas A; Heuschkel R; Mitton S; Mitchell B; Daniels R; Libonati MA; Zanker S; Kugathasan S;
    J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):185-91. PubMed ID: 17255829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
    Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
    Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
    Feagan BG; Greenberg GR; Wild G; Fedorak RN; Paré P; McDonald JW; Dubé R; Cohen A; Steinhart AH; Landau S; Aguzzi RA; Fox IH; Vandervoort MK
    N Engl J Med; 2005 Jun; 352(24):2499-507. PubMed ID: 15958805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
    Lawson MM; Thomas AG; Akobeng AK
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.
    Evans RC; Clarke L; Heath P; Stephens S; Morris AI; Rhodes JM
    Aliment Pharmacol Ther; 1997 Dec; 11(6):1031-5. PubMed ID: 9663825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis.
    Madsen SM; Schlichting P; Davidsen B; Nielsen OH; Federspiel B; Riis P; Munkholm P
    Am J Gastroenterol; 2001 Jun; 96(6):1807-15. PubMed ID: 11419834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.
    O'Connor PW; Goodman A; Willmer-Hulme AJ; Libonati MA; Metz L; Murray RS; Sheremata WA; Vollmer TL; Stone LA;
    Neurology; 2004 Jun; 62(11):2038-43. PubMed ID: 15184611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
    Sands BE; Kozarek R; Spainhour J; Barish CF; Becker S; Goldberg L; Katz S; Goldblum R; Harrigan R; Hilton D; Hanauer SB
    Inflamm Bowel Dis; 2007 Jan; 13(1):2-11. PubMed ID: 17206633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.
    Probert CS; Hearing SD; Schreiber S; Kühbacher T; Ghosh S; Arnott ID; Forbes A
    Gut; 2003 Jul; 52(7):998-1002. PubMed ID: 12801957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.
    Tubridy N; Behan PO; Capildeo R; Chaudhuri A; Forbes R; Hawkins CP; Hughes RA; Palace J; Sharrack B; Swingler R; Young C; Moseley IF; MacManus DG; Donoghue S; Miller DH
    Neurology; 1999 Aug; 53(3):466-72. PubMed ID: 10449105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
    Drugs R D; 2004; 5(2):102-7. PubMed ID: 15293871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
    Ford AC; Sandborn WJ; Khan KJ; Hanauer SB; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):644-59, quiz 660. PubMed ID: 21407183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.